Merck's COVID Anti-Viral Candidate Invites Reconsideration of Ivermectin and HCQ
newsletter.allfactsmatter.us
The biggest COVID headline today is Merck’s announcement that it is seeking FDA approval (emergency use authorization) for its antiviral therapeutic molnupiravir, after clinical trial results showed the medication is as an highly effective treatment for COVID-19, the disease caused by SARS-CoV-2 infection.
Merck's COVID Anti-Viral Candidate Invites Reconsideration of Ivermectin and HCQ
Merck's COVID Anti-Viral Candidate Invites…
Merck's COVID Anti-Viral Candidate Invites Reconsideration of Ivermectin and HCQ
The biggest COVID headline today is Merck’s announcement that it is seeking FDA approval (emergency use authorization) for its antiviral therapeutic molnupiravir, after clinical trial results showed the medication is as an highly effective treatment for COVID-19, the disease caused by SARS-CoV-2 infection.